AGNPF Stock Chart & Stats
$0.29
<$0.01(2.24%)
At close: 4:00 PM EDT
$0.29
<$0.01(2.24%)
Day’s Range― - ―
52-Week Range$0.22 - $0.67
Previous CloseN/A
Volume260.00
Average Volume (3M)7.73K
Market Cap
$2.23M
Enterprise Value$3.70
Total Cash (Recent Filing)$210.03K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.17
Next Earnings
Dec 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.62
Shares Outstanding8,923,237
10 Day Avg. Volume2,484
30 Day Avg. Volume7,733
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.77
Price to Sales (P/S)0.00
P/FCF Ratio-1.78
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.35
Revenue Forecast (FY)$817.44K
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetHaving no debt materially reduces fixed financing obligations and interest risk, giving management flexibility to allocate scarce cash to R&D or trials. Over 2-6 months this lowers default risk, supports negotiating power with partners/investors and improves downside protection.
Improving Loss TrendA materially narrower net loss over recent years signals improving cost control or operating efficiency. If sustained, this trend reduces future financing needs and indicates operational progress toward a repeatable model, making eventual path-to-profitability more credible.
Focused Digital Therapeutics StrategyA clear strategic focus on mental and neurological digital therapeutics concentrates R&D and regulatory efforts, fostering domain expertise. Over months this specialization can produce differentiated products, clearer go-to-market positioning and stronger partnerships within a persistent care segment.
Bears Say
No Revenue BaseZero reported revenue means the company has not yet proven a commercial product or market fit. Without revenue validation, long-term sustainability depends on continued financing, increasing execution risk and uncertainty around customer adoption and durable cash generation.
Persistent Negative Cash FlowConsistent negative operating and free cash flow signals ongoing cash burn and a reliance on external capital. Over the next several months this constrains investment, raises dilution and refinancing risk, and limits the firm's ability to scale without new funding.
Very Limited Operating ScaleAn extremely small headcount constrains product development, clinical/regulatory work and commercialization capacity. This limited scale increases dependence on external partners and makes consistent execution and timely regulatory progress more fragile over a multi-month horizon.
Grey Matters Health News
AGNPF FAQ
What was Grey Matters Health’s price range in the past 12 months?
Grey Matters Health lowest stock price was $0.22 and its highest was $0.67 in the past 12 months.
What is Grey Matters Health’s market cap?
Grey Matters Health’s market cap is $2.23M.
When is Grey Matters Health’s upcoming earnings report date?
Grey Matters Health’s upcoming earnings report date is Dec 18, 2026 which is in 137 days.
How were Grey Matters Health’s earnings last quarter?
Grey Matters Health released its earnings results on Jul 29, 2026. The company reported -$0.093 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Grey Matters Health overvalued?
According to Wall Street analysts Grey Matters Health’s price is currently Overvalued.
Does Grey Matters Health pay dividends?
Grey Matters Health does not currently pay dividends.
What is Grey Matters Health’s EPS estimate?
Grey Matters Health’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Grey Matters Health have?
Grey Matters Health has 8,923,237 shares outstanding.
What happened to Grey Matters Health’s price movement after its last earnings report?
Grey Matters Health reported an EPS of -$0.093 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Grey Matters Health?
Currently, no hedge funds are holding shares in AGNPF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Grey Matters Health
Grey Matters Health Inc. operates as a clinical stage pharmaceutical development company in Canada and Australia. The company focuses on developing the therapeutic drugs in the areas of non-alcoholic steatohepatitis, liver disease, chronic kidney disease, and stroke program. Its pipeline includes repirinast for the treatment of chronic kidney disease; and N,N-Dimethyltryptamine for the treatment of strokes and traumatic brain injuries. The company was formerly known as Algernon Health Inc. and changed its name to Grey Matters Health Inc. in April 2026. Algernon Health Inc. was incorporated in 2015 and is headquartered in Vancouver, Canada.
Technical Analysis
Appili Therapeutics Inc Class A
―
Rakovina Therapeutics Inc
―
Universal Ibogaine Inc
―
Mindbio Therapeutics Corp.
―
Neural Therapeutics Inc.
―